The most common BRAF mutation in ovarian low-grade serous neoplasms (LGSNs) involves substitution of valine by glutamic acid at position 600 (V600E). Small studies have demonstrated high specificity of immunohistochemistry with mutation-specific monoclonal antibody VE1. We sought to investigate the expression of VE1 protein in LGSNs and its correlation with BRAF mutation-associated histological features and BRAF mutation status. Methods and results: We reviewed pathology reports and available slides from ovarian serous borderline tumours (SBTs) and low-grade serous carcinomas (LGSCs) diagnosed between 2000 and 2012. VE1 immunohistochemistry was performed on formalinfixed, paraffin-embedded tissue sections. Tumours with ≥50% positive cells were considered positive. Of 121 LGSNs, there were 73 SBTs, eight SBTs with micropapillary features (mpSBT) and 40 LGSCs (22 primary, 18 metastatic). VE1 was positive in 52% (38 of 73) of SBTs and 9% (two of 22) of primary LGSCs, and in none of the mpSBTs and metastatic LGSCs (P < 0.0001). Of 76 tumours with known mutation status, 42 (55%) harboured mutations, including BRAF V600E (26, 34%), KRAS
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(eight, 11%). BRAF V600E mutations were present in 48% (25 of 52) of SBTs and 5% (one of 22) of LGSCs (P < 0.0001). VE1 was positive in 96% (25 of 26) of BRAF V600E -mutated tumours and correlated with BRAF mutation-associated histological features (P < 0.0001).
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Introduction
Low-grade serous carcinomas (LGSCs) of the ovary represent slow-growing, genetically stable neoplasms, typically confined to the ovary, and lacking TP53 mutations. [1] [2] [3] LGSCs may occur de novo or evolve in a stepwise fashion, from epithelial inclusions to benign serous cystadenomas or adenofibromas and serous borderline tumours (SBTs). 2, 4, 5 SBTs and LGSCs are characterised commonly by activating somatic mutations in the KRAS oncogene and its downstream mediator, BRAF. KRAS and BRAF mutations are usually mutually exclusive in these tumours, with reported mutation frequencies of up to 54% for KRAS and up to 48% for BRAF. BRAF mutations have been reported in 23-48% of SBTs but in only 0-6% of LGSCs. [6] [7] [8] [9] [10] [11] BRAF encodes a protein from the RAF family of serine/threonine protein kinases, involved in regulating the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cell signalling pathway. The most common BRAF mutation involves substitution of valine by glutamic acid at position 600 (V600E) and has been described in various tumours, such as melanoma, hairy cell leukaemia, colorectal carcinoma, papillary thyroid carcinoma and non-small cell carcinoma of the lung. 12, 13 Immunohistochemistry with anti-BRAF V600E monoclonal antibody VE1 has been shown to be a sensitive and specific method for detection of BRAF V600E mutation in ovarian serous tumours in small studies. [14] [15] [16] Given that BRAF V600E -mutated SBTs exhibit morphological features that may be misinterpreted as micropapillary SBT (mpSBT; a variant of SBT associated more frequently with advanced stage and LGSC), 17 accurate identification of BRAF V600E -mutated SBTs is clinically important. We sought to investigate expression of VE1 protein in low-grade serous neoplasms of the ovary, and its association with BRAF V600E mutation-associated histological features and BRAF V600E mutation status.
Materials and methods
This study was performed in accordance with institutional ethics committee guidelines (protocol no. 16-1684; Memorial Sloan Kettering Cancer Center Institutional Review Board; approved 23 December 2016). Through a search of our institutional database, we identified patients diagnosed with SBTs and LGSCs of the ovary between 2000 and 2012. We reviewed pathology reports and available haematoxylin and eosin-stained slides. Briefly, diagnostic criteria used were as follows -SBT: hierarchical branching of irregular papillae with detached cell clusters and single cells (budding), fibromatous to oedematous fibrovascular cores, with or without luminal mucin; mpSBT: fibromatous to oedematous papillae lined by delicate, filiform papillae lacking fibrovascular cores (95 longer than wide; the minimum size criterion of 5 mm is not used at our institution) or fused papillae imparting a cribriform appearance; and LGSC: destructive stromal invasion with micropapillae, macropapillae or single cells, or solid growth measuring >5 mm. We recorded histological features associated with the BRAF V600E mutation, including the presence of epithelial cells with abundant eosinophilic cytoplasm, discrete cell borders, cell budding and detachment, as described previously. 18, 19 Tumours exhibiting at least two of these features (eosinophilic cytoplasm and cell budding) were considered positive for BRAF V600E mutation-associated histological features.
Immunohistochemistry was performed on 4-lmthick archival formalin-fixed paraffin-embedded (FFPE) tissue sections using the mouse monoclonal anti-BRAF V600E antibody, clone VE1 (dilution 1:800, catalogue number E19294; Spring Bioscience, Pleasanton, CA, USA) on a Bond III automated staining system (Leica Biosystems, Buffalo Grove, IL, USA), according to the manufacturer's instructions. Heat-induced antigen retrieval was performed using epitope retrieval solution 2 (ER2, pH 8.0) (Leica Biosystems) for 40 min. Primary antibody was incubated for 30 min followed by the 3,3 0 -diaminobenzidine-based Bond Polymer Refine detection system (Leica Biosystems). Cytoplasmic expression of VE1 was scored based on the percentage of positive cells as follows: 0-10%, 25%, 50%, 75% and 90%. Tumours with ≥50% positive tumour cells were considered positive for VE1 expression, as described previously. 20 A subset of tumours was tested for BRAF V600E and KRAS mutations. FFPE tissue samples were macrodissected to enrich for tumour cellularity of at least 80%. DNA extraction was performed using the DNeasy tissue kit, according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). BRAF and KRAS hotspot mutations were then detected using a custom iPLEX assay (Sequenom, Inc., San Diego, CA, USA). These variants were reviewed manually, and in tumours with sufficient DNA and hotspot mutations mutation status were confirmed with an orthogonal method, as described previously.
S T A T I S T I C A L A N A L Y S E S
Statistical analyses were performed using the software package SPSS version 24.0. Associations between clinicopathological covariates and gene mutation or VE1 protein expression status were assessed using contingency tables, and significance of associations was determined using Pearson's v 2 test or Fisher's exact test, as appropriate. A significance level of P < 0.05 was used for all comparisons.
Results
The study cohort comprised 121 low-grade serous neoplasms, including 73 SBTs, eight mpSBTs and 40
LGSCs ( Mutation status was available in 76 (63%) tumours, including 52 SBTs, two mpSBTs and 22
LGSCs (12 primary, 10 metastatic). Of these 76 tumours, 42 (55%) harboured BRAF V600E or KRAS mutations. Mutations were more common in SBTs compared to other groups (P < 0. LGSCs (P = 0.006) ( Table 1) . Immunohistochemical expression of VE1 was identified in 96% (25 of 26) of tumours with BRAF V600E mutation, while only two of 27 (7%) VE1-positive tumours were negative for BRAF V600E mutation (P < 0.0001). The sensitivity, specificity, positive predictive value and negative predictive value for VE1 immunohistochemistry were 96, 96, 93 and 98%, respectively.
Of the 52 SBTs with known mutation status, BRAF mutation-associated histological features were identified in 38 (73%) tumours. VE1 was positive in 26 (50%) tumours, and 25 (48%) harboured a BRAF V600E mutation (P < 0.0001). All the 25 BRAF V600E -mutated tumours were positive for VE1 by immunohistochemistry. In addition, one of two mpSBTs showed BRAF mutation-associated histological features. However, none of the mpSBTs was positive for VE1 by immunohistochemistry or BRAF V600E mutation. The sensitivity, specificity, positive predictive value and negative predictive value for BRAF mutation-associated histological features were 92%, 70%, 62% and 95%, respectively.
Discussion

SBTs and
LGSCs are low-grade serous neoplasms of the ovary that co-exist in approximately 75% of cases. These tumours are diagnosed typically in younger women, with a mean age of 42 years for SBTs and 56 years for LGSCs. Although most patients with SBTs have a benign clinical course, recurrences and progression to LGSC have been described in approximately 15% and 5% of patients, respectively. 21, 22 Transformation to high-grade serous carcinoma is extremely rare. Predictors for progression include advanced stage, type of extraovarian disease, micropapillary architecture and the presence of microinvasive carcinoma. 22 Primary treatment of LGSC includes surgery combined with chemotherapy or hormonal therapy, while patients with recurrent disease generally receive multiple lines of systemic therapy and ultimately die from their disease. 23 Median overall survival rates for LGSC range from 82 to 126 months. 24, 25 Secondary cytoreduction without gross residual disease has been shown to improve overall survival to 167.5 months versus 88.9 months in patients with gross residual disease. 26 Furthermore, patients with microscopic residual disease had a longer median progression-free (33.2 months versus ≤14.7 months) and overall survival (96.9 months versus ≤44.5 months) compared with those with >0.1 cm residual disease (P < 0.001).
Patients with measurable residual LGSC had a similar adjusted hazard ratio for death (2.12 versus 2.31; P = 0.002 and P < 0.001, respectively) as patients with high-grade serous carcinoma. 27 This is due most probably to the relative resistance of LGSCs to cytotoxic chemotherapy. 27, 28 In genomic profiling studies, LGSCs cluster with SBTs but differ from high-grade serous carcinomas in having higher expression of hormone receptors, frequent KRAS and BRAF mutations, lower rates of TP53 mutations and activation of the MAPK pathway. 23, 29 Recurrent disease is treated generally with salvage chemotherapy, hormonal therapy or targeted therapies, such as inhibitors of vascular endothelial growth factor A (e.g. bevacizumab), inhibitors of MAPK enzymes MEK1/2 (e.g. selumetinib, binimetinib, trametinib) and BRAF inhibitors (e.g. vemurafenib), have been explored in clinical trials. 23, [29] [30] [31] [32] [33] [34] In our study, V600E BRAF V600E mutations were present in 48% (25 of 52) of SBTs and 5% (one of 22) of all LGSCs. BRAF mutations have been described in up to 48% of SBTs. [6] [7] [8] [9] [10] [11] Some studies have reported BRAF mutations in 19-33% of LGSCs. 6, 35 However, lower mutation frequencies (0-6%) demonstrated by later studies, especially in advanced stage LGSCs, 7, 9, 33, 36 may suggest that biologically aggressive LGSCs are more likely to arise from SBTs lacking BRAF mutations. 7, 9 KRAS and BRAF mutation status has been shown to be a prognostic factor in LGSC. Patients with KRAS or BRAF mutations show significantly better overall survival than those lacking mutations [21 versus 58 patients, 106.7 months, 95% confidence interval (CI) = 50.6-162.9 versus 66.8 months, 95% CI = 43.6.0-90.0, respectively (P = 0.018)]. 36 Patients with LGSC harbouring BRAF V600E mutation also have a better prognosis compared with those without mutation. 9 Patients with BRAF-mutated SBTs have been shown to present at earlier stages. 37 However, no significant differences were found in overall survival or diseasefree survival among BRAF-mutated and non-mutated SBTs or LGSCs in some studies. Several small studies have reported sensitivity and specificity of VE1 immunohistochemistry. One study described VE1 positivity in 13% (four of 31) of SBTs and 5% (three of 62) of LGSCs, with one of six SBTs being falsely positive. 15 Another study reported positive VE1 in 27% (three of 11) of SBTs, with 100% concordance with competitive allele-specific hydrolysis probe polymerase chain reaction (CAST-PCR) and 68% concordance with Sanger sequencing. 20 The largest study of VE1 immunohistochemistry reported positive results in 71% (22 of 31) of SBTs and 14% (one of seven) of LGSCs, with 100% concordance with PCR. 16 The latest report found VE1 expression in 14% (one of seven) of SBTs and 0% (none of 35) of LGSCs. In addition, one benign lesion described as 'serous superficial papilloma' and one serous cystadenoma with focal proliferation were positive. All three VE1-positive lesions showed BRAF V600E mutation by PCR. 38 Our study includes the largest number of SBTs reported to date. In our study, VE1 was positive in 52% (38 of 73) of all cases of SBTs and 9% (two of 22) of primary LGSCs, and in none of the mpSBTs or metastatic LGSCs. Of the 76 tumours with known mutation status, VE1 was positive in 50% (26 of 52) of SBTs compared with only 5% (one of 22) of all LGSCs, and all 25 SBTs with BRAF V600E mutation were positive for VE1.
BRAF-mutated SBTs have been reported to show specific morphological features, including abundant eosinophilic cytoplasm, well-defined cell borders, bland nuclei and cell budding. 18 At least two of these features were identified in all 25 SBTs with BRAF V600E mutation, in contrast to only 11% (five of 47) of SBTs lacking BRAF V600E mutation. The eosinophilic cells have been reported to show immunohistochemical expression of p16, a senescence-associated marker, associated with a lower Ki-67 proliferation index compared to adjacent non-eosinophilic cells. 18 In our study, the presence of BRAF V600E mutationassociated histological features was associated significantly with positive VE1 immunohistochemistry (P < 0.0001), and most tumours with BRAF V600E mutation (96%; 25 of 26) were VE1-positive (P < 0.0001). Of note, BRAF V600E mutation-associated SBTs can form micropapillae that differ from those of mpSBT but may lead to diagnostic confusion. Given the association of mpSBTs with invasive implants (LGSC), 17 it is very important to distinguish the two entities. Identification of at least two specific histological features and/or VE1 immunohistochemistry can be discriminatory in diagnostically challenging cases. BRAF mutations are thought to mediate progression of serous cystadenomas to SBTs. 39 In contrast, in-vitro experiments have demonstrated that induction of BRAF V600E expression leads to the development of the aforementioned BRAF mutation-associated histological features in cultured epithelial cells. 18 The association of BRAF mutations with this cellular senescence phenotype and up-regulation of tumour suppressor genes in SBTs suggest that BRAF mutations may have a protective role against the progression of SBT to LGSC.
18,39 BRAF mutation analysis of SBTs also suggests that peritoneal implants are derived from the primary ovarian tumour with overall concordance of BRAF mutations between ovarian SBTs and peritoneal implants reported to be 95% (59 of 62) (P < 0.00001). 40 In conclusion, BRAF V600E mutations are significantly more common in SBTs than in LGSCs. Immunohistochemical expression of VE1 protein is associated strongly with BRAF V600E mutation status and specific histological features. VE1 immunohistochemistry is a reliable method for the detection of BRAF V600E mutations and is faster, less expensive and readily accessible to more laboratories than mutation testing.
